2002
DOI: 10.1073/pnas.242600099
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Adoptive T cell therapy, involving the ex vivo selection and expansion of antigen-specific T cell clones, provides a means of augmenting antigen-specific immunity without the in vivo constraints that can accompany vaccine-based strategies. A phase I study was performed to evaluate the safety, in vivo persistence, and efficacy of adoptively transferred CD8 ؉ T cell clones targeting the tumor-associated antigens, MART1͞MelanA and gp100 for the treatment of patients with metastatic melanoma. Four infusions of aut… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

17
788
1
4

Year Published

2003
2003
2019
2019

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 1,051 publications
(810 citation statements)
references
References 30 publications
17
788
1
4
Order By: Relevance
“…29 Other studies with CD8 or CD4 knockout mice, bearing B16 melanoma, revealed the central role of CD41 cells in the antitumor immune response, since CD8 -/-mice were able to reject a tumor challenge. 30 It is currently accepted that activating of both tumor-specific CD8 and CD4 cells is important to establish optimal immunity to cancer.…”
Section: Discussionmentioning
confidence: 99%
“…29 Other studies with CD8 or CD4 knockout mice, bearing B16 melanoma, revealed the central role of CD41 cells in the antitumor immune response, since CD8 -/-mice were able to reject a tumor challenge. 30 It is currently accepted that activating of both tumor-specific CD8 and CD4 cells is important to establish optimal immunity to cancer.…”
Section: Discussionmentioning
confidence: 99%
“…[2]). ACT is capable of mediating tumor regression [3][4][5][6], however, these effects are even more pronounced in the absence of host lymphocytes [7,8]. This approach has resulted in the most consistent and dramatic clinical responses observed in the treatment of metastatic cancer [7] (Figure 1a).…”
Section: Introductionmentioning
confidence: 99%
“…Although the immunogenicity of a number of TAA has been documented in clinical trials, their therapeutic potential has not been clearly assessed, with the exception of the Melan-A/MART-1 antigen. Indeed, the therapeutic usefulness of the Melan-A antigen in melanoma is supported by the analysis of several active [2,3] and passive [4][5][6][7][8][9] immunotherapy protocols targeting this antigen.…”
Section: Introductionmentioning
confidence: 99%